Form 4 for QNRX Quoin Pharmaceuticals Ltd.

Accepted 2026-09-01 21:39:55 ET · period of report 2026-08-31 · accession 0001104659-26-104404 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2026-09-01 21:39	2026-08-31	QNRX	Myers Michael	CEO, Dir	P - Purchase	$4.88	+20.5K	37.7K	+119%	+$100.0K
D	2026-09-01 21:39	2026-08-31	QNRX	Myers Michael	CEO, Dir	P - Purchase	—	+10.2K	10.2K	New	—

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	ADSs	2026-08-31	P	A	20,490	$4.88	37,713	D	—	—	(F1) Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer. (F2) Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88.
2	Derivative	Ordinary Warrants (Right to Buy)	2026-08-31	P	A	10,245	—	10,245	D	$6.10 · 2026-08-31 to —	10,245 ADS	(F2) Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88. (F2) Purchased in Issuer's private placement of ADSs with 50% warrant coverage. The ADSs and accompanying ordinary warrants ("Warrants") were issued at a combined purchase price of $4.88. (F3) The Warrants were exercisable immediately upon issuance, subject to a beneficial ownership cap. (F4) The Warrants will expire on the earlier of (i) five (5) years from the date of issuance or (ii) 30 days after the Issuer's public announcement that the primary endpoint has been met in the clinical trial CL-QRX003-004 for the treatment of Netherton Syndrome. (F1) Ordinary Shares are represented by American Depositary Shares ("ADSs"). Each ADS represents thirty-five (35) ordinary shares of the Issuer.